The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.
 
Andrea B. Apolo
No Relationships to Disclose
 
Daniel da Motta Girardi
No Relationships to Disclose
 
Scot Anthony Niglio
Stock and Other Ownership Interests - Gilead Sciences; Regeneron
Other Relationship - STEMCELL Technologies (I)
 
Rosa Maria Nadal
No Relationships to Disclose
 
Lisa M. Cordes
No Relationships to Disclose
 
Seth M. Steinberg
No Relationships to Disclose
 
Rene Costello
No Relationships to Disclose
 
Jane B Trepel
Research Funding - AstraZeneca (Inst); EpicentRX (Inst); Syndax (Inst)
 
Sunmin Lee
No Relationships to Disclose
 
Min-Jung Lee
No Relationships to Disclose
 
Liang Cao
No Relationships to Disclose
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Merck (Inst); NantBioScience (Inst); Pfizer (Inst)
 
Donald P. Bottaro
Patents, Royalties, Other Intellectual Property - Bottaro DP, Athauda G, Burgess TL. US Patent No. 7,964,365; June 21, 2011: Methods for Diagnosing and Monitoring the Progression of Cancer. Related International Publication No. WO/2007/056523.; Bottaro DP, Athauda G, Burgess TL. US Patent No. 8,304,199; November 6, 2012: Methods for Diagnosing and Monitoring the Progression of Cancer by Measuring Soluble c-Met Ectodomain.; Bottaro DP, Athauda G, Burgess TL. US Patent No. 8,617,831; December 31, 2013: Methods for Diagnosing and Monitoring the Progression of Cancer by Measuring Soluble c-Met Ectodomain.; Bottaro DP, Cecchi F. US Patent No. 10,035,833, July 31, 2018: Vascular Endothelial Growth Factor Antagonists and Methods of Making.; Bottaro DP, Cecchi F. US Patent No. 9,550,818, January 24, 2017: Methods for Use of Vascular Endothelial Growth Factor Antagonists. Related International Publication No. WO/2013/163606.; Bottaro DP, Giubellino A, Atabey N, Soriano JV, Breckenridge DE, Burke TR Jr. US Patent No. 7,871,981; January 18, 2011: Inhibition of Cell Motility, Angiogenesis and Metastasis. Related International Publication No. WO/2001/028577.; Bottaro DP, Peach M, Nicklaus M, Burke TR Jr, Athauda G, Choyke S, Giubellino A, Tan N, Shi Z-D. US Patent No. 8,754,081; June 17, 2014: Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling. Related International Pu; Bottaro DP, Peach M, Nicklaus M, Tan N. US Patent No. 8,569,360; October 29, 2013: Compositions and Methods for Inhibition of Hepatocyte Growth Factor Receptor c-Met Signaling. Related International Publications No. WO/2009/124024 and WO/2009/124013.; Bottaro DP, Petryshyn R. US Patent No. 6,326,466; December 4, 2001: Double Stranded RNA Dependent Protein Kinase Derived Peptides to Promote Proliferation of Cells and Tissues in a Controlled Manner. Related International Publication No. WO/1998/004717.; Bottaro DP, Soriano JV, Atabey SN, Breckenridge DE, Gao Y, Yao Z-J, Burke TR Jr. US Patent No. 7,132,392; November 7, 2006: Inhibition of Cell Motility and Angiogenesis by Inhibitors of Grb2-SH2-Domain. Related International Publications No. WO/2001/02857; Chan AML, Rubin JS, Bottaro DP, Aaronson SA, Stahl SJ, Wingfield PT, Cioce V. US Patent No. 7,605,127; October 20, 2009: Truncated Hepatocyte Growth Factor Variant Protein HGF/NK2. Related International Publication No. WO/1996/040914.; Chan AML, Rubin JS, Bottaro DP, Aaronson SA. US Patent No. 6,566,098; May 20, 2003: DNA Encoding Truncated Hepatocyte Growth Factor Variants. Related International Publication No. WO/1992/005184.
 
Biren Saraiya
Honoraria - Eisai; Sanofi
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Janssen
Research Funding - Aragon Pharmaceuticals (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst)
 
Howard L. Parnes
Stock and Other Ownership Interests - Editas Medicine; Gilead Sciences; Health Care Select Sector; Illumina; Intellia Therapeutics; Intuitive Surgical; IQvia; Novartis; Roche; Roper Technologies; Schlumberger
 
William L. Dahut
No Relationships to Disclose
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Consulting or Advisory Role - Debiopharm Group; Pfizer; Seagen
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)